Prognostic relevance of CD163+ immune cells in patients with metastatic breast cancer.

MLA

Lindberg, Ida, et al. “Prognostic Relevance of CD163+ Immune Cells in Patients with Metastatic Breast Cancer.” Cancer Immunology, Immunotherapy, vol. 74, no. 2, Feb. 2025, pp. 1–14. EBSCOhost, https://doi.org/10.1007/s00262-024-03892-2.

APA

Lindberg, I., Saleh, A., Tutzauer, J., Gunnarsdottir, F. B., Rydén, L., Bergenfelz, C., & Larsson, A.-M. (2025). Prognostic relevance of CD163+ immune cells in patients with metastatic breast cancer. Cancer Immunology, Immunotherapy, 74(2), 1–14. https://doi.org/10.1007/s00262-024-03892-2

Chicago

Lindberg, Ida, Aya Saleh, Julia Tutzauer, Frida Björk Gunnarsdottir, Lisa Rydén, Caroline Bergenfelz, and Anna-Maria Larsson. 2025. “Prognostic Relevance of CD163+ Immune Cells in Patients with Metastatic Breast Cancer.” Cancer Immunology, Immunotherapy 74 (2): 1–14. doi:10.1007/s00262-024-03892-2.